Association between hemoglobin A1c variability and subclinical coronary atherosclerosis in subjects with type 2
Hae Kyung Yang1, Borami Kang1, Seung-Hwan Lee1
1Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Insights
High hemoglobin A1c (HbA1c) variability, not just the average, is linked to coronary artery disease in type 2 diabetes patients. Stabilizing blood glucose may prevent early heart issues.
Area of Science:
- Cardiology
- Endocrinology
- Diabetology
Background:
- Type 2 diabetes (T2D) management often focuses on average blood glucose control.
- However, blood glucose fluctuations (variability) may also impact cardiovascular health.
- Subclinical coronary atherosclerosis is a key indicator of cardiovascular risk.
Purpose of the Study:
- To investigate the association between hemoglobin A1c (HbA1c) variability and subclinical coronary atherosclerosis in individuals with T2D.
- To determine if HbA1c variability is an independent risk factor for coronary artery disease in this population.
Main Methods:
- Retrospective analysis of coronary computed tomography data from 595 T2D patients without prior cardiovascular disease.
- Calculation of HbA1c variability metrics: intraindividual standard deviation (HbA1c-SD) and coefficient of variation (HbA1c-CV).
- Definition of subclinical coronary atherosclerosis as a coronary calcium score >400.
Main Results:
- Higher HbA1c variability (both HbA1c-SD and HbA1c-CV) was associated with a greater prevalence of subclinical coronary atherosclerosis.
- This association remained significant even after adjusting for mean HbA1c levels in patients with diabetes duration of 10 years or less.
- Odds ratios for subclinical coronary atherosclerosis were 2.894 for higher HbA1c-SD and 2.540 for higher HbA1c-CV.
Conclusions:
- Long-term blood glucose stabilization is crucial for preventing subclinical coronary atherosclerosis in early-stage type 2 diabetes.
- HbA1c variability is an important, independent predictor of coronary artery disease in T2D patients.
- Clinical focus should include managing glucose fluctuations alongside average HbA1c levels.
Aims:
We examined the association between hemoglobin A1c (HbA1c) variability and subclinical coronary atherosclerosis in subjects with type 2 diabetes.
Methods:
We used the multidetector coronary computed tomography data collected from subjects with type 2 diabetes who did not have a history of cardiovascular disease or angina symptoms. HbA1c measurements preceding the date of cardiac imaging were retrospectively collected, and intraindividual SD (HbA1c-SD), CV and adjusted SD of HbA1c measurements were calculated. Subclinical coronary atherosclerosis was defined as calcium score >400 without any cardiac symptoms.
Results:
A total of 595 subjects were categorized according to the median value of each HbA1c variability indicators. The prevalence of subclinical coronary atherosclerosis was higher in higher HbA1c variability group compared with lower HbA1c variability group. Multivariable logistic regression analysis showed that higher HbA1c-SD and -CV were associated with the presence of subclinical coronary atherosclerosis, independent of mean HbA1c level in subjects with diabetes duration ≤10 years (OR [95% CI]; HbA1c-SD, 2.894 [1.105-7.584]; HbA1c-CV, 2.540 [1.022-6.316]).
Conclusions:
Long-term stabilization of blood glucose level might be important in preventing subclinical coronary atherosclerosis in subjects with earlier period of type 2 diabetes.
Related Concept Videos
Coronary Artery Disease I: Introduction
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Symptoms, Diagnosis, and Complications
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation


